Physician profile

Timothy B Cole

Surgery · Mckinney, TX

NPI 1215930144

$12,219.83

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Travel and Lodging$1,169.26
Food and Beverage$421.56
Gift$16.25

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Intuitive Surgical, INC. $10,827.13 2022-2023 Da Vinci Surgical System
W. L. Gore & Associates, INC. $619.19 2019
Davol INC. $309.12 2019-2022
Thd America, INC. $134.46 2020
Endogastric Solutions, INC $125.00 2022
Acell, INC. $120.18 2019
Teleflex LLC $28.30 2023 Weck
Bolder Surgical LLC $21.71 2019-2020
Medtronic, INC. $18.90 2021
Allergan, INC. $15.84 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Timothy B Cole

$12,219.83

in general payments reported 2019-2025

Years
2019-2023
Top company
Intuitive Surgical, INC.

https://glasscript.com/doctor/100008/timothy-b-cole

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.